SS Innovations to Participate in Upcoming Investor Conferences
Rhea-AI Summary
SS Innovations (NASDAQ: SSII) announced that its executives will participate in two investor conferences in November 2025. Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will attend the UBS Global Healthcare Conference in Palm Beach Gardens on November 11, 2025 and the Stifel 2025 Healthcare Conference in New York on November 12, 2025. Management will be available for one-on-one and small group meetings on both days. A live webcast and replay of the Stifel group presentation will be accessible on the company’s investor website at https://ssinnovations.com/investor-overview/.
Positive
- None.
Negative
- None.
News Market Reaction 6 Alerts
On the day this news was published, SSII declined 0.70%, reflecting a mild negative market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $1.80B at that time.
Data tracked by StockTitan Argus on the day of publication.
FORT LAUDERDALE, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia Pacific, are scheduled to participate in the following upcoming investor conferences:
UBS Global Healthcare Conference
Palm Beach Gardens, FL
Tuesday, November 11, 2025
Management will be available for one-on-one and small group meetings throughout the day.
Stifel 2025 Healthcare Conference
New York, NY
Wednesday, November 12, 2025
Group presentation: 4:40 p.m. Eastern Time
Management will be available for one-on-one and small group meetings throughout the day.
A live webcast and replay of the Stifel group presentation will be accessible on the Company’s website at https://ssinnovations.com/investor-overview/.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
As of September 30th, 2025, the SSi Mantra cumulative installed base totaled 125 across six countries where the Company’s surgical robotic system has received regulatory approval. To date, 119 hospitals have installed the SSi Mantra and over 6,000 surgical procedures have been performed, including 60 telesurgeries and 310 cardiac procedures.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
FAQ
When will SS Innovations (SSII) present at the UBS Global Healthcare Conference?
What time is the SS Innovations group presentation at the Stifel 2025 Healthcare Conference (SSII)?
Will SS Innovations (SSII) offer one-on-one meetings at the November 2025 conferences?
Where can investors watch the SS Innovations (SSII) Stifel presentation webcast and replay?
Which SS Innovations executives will attend the November 2025 investor conferences?
What topics will SS Innovations (SSII) cover at the investor conferences?
